Status:
TERMINATED
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Lead Sponsor:
Fate Therapeutics
Conditions:
Advanced Solid Tumor
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study F...
Detailed Description
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study ...
Eligibility Criteria
Inclusion
- Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
- Subjects who have provided Informed consent prior to their study participation
Exclusion
- Not Applicable
Key Trial Info
Start Date :
June 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 11 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04106167
Start Date
June 11 2019
End Date
August 11 2023
Last Update
September 21 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD Moores Cancer Center
San Diego, California, United States, 92093
2
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States, 55455
3
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
4
MD Anderson Cancer Center
Houston, Texas, United States, 77030